卡托普利联合丹参酮Ⅱa磺酸钠治疗肺心病心衰临床观察

Clinical Observation of Kato Pury Combined with Sodium Tanshinone Ⅱa Sulfonate in Treatment of Pulmonary Heart Disease with Heart Failure

目的:观察卡托普利联合丹参酮IIa磺酸钠治疗肺心病心衰效果。方法:选取2009年5月～2013年5月收治的57例肺心病患者,将其随机分为观察组30例,对照组27例。对照组常规给予抗感染、止咳化痰平喘、扩血管、强心、利尿等治疗,观察组在对照组治疗基础上停用扩血管药物,将强心利尿药物减量至原来的1/2,并给予卡托普利口服及丹参酮IIa磺酸钠静脉点滴。2 w之后观察2组患者临床症状体征及肺动脉收缩压等改善情况。结果:2组患者的病情均有改善,效果差异显著,观察组患者有效率可达86.67%,对照组有效率达66.67%,有统计学意义(P<0.05)。2组肺动脉收缩压均有降低,观察组效果更明显(P<0.05)。结论:卡托普利联合丹参酮IIa磺酸钠治疗慢性肺心病心衰效果佳,且药物价格低廉,不良反应少,值得临床推广应用。

Objective： To observe the effect and adverse reaction of Kato Pury combined with sodium tanshinone lla sulfonate in treatment of pulmonary heart disease with heart failure. Methods： 57 cases of patients with pulmonary heart disease from 2009 May to 2013 May were selected, and randomly divided into observation group of 30 cases, 27 cases in the control group. The control group were given conventional anti infection, removing phlegm, an＇esting cough anti relieving asthma, vascular dilation, strengthening heart and diuresis. Tile observation group didn＇t use the asodilator drugs on the basis of the treatment of control group, anti the slrengthening heart anti diuresis drug were extenuated to the origiual 1/2, and given the Kato Pury oral and intravenous sodium tanshinone flu sulfou- ate. To observed the improvement of the clinical symptoms and pulmonary artery systolic pressure in two groups 2 weeks later. Results： Both of the two groups of patients x^ere improved, but there was a significant difference. The patients in observation group ett^ciency was up to 86. 67%, the effective rate of control gn＇oup was 66. 67% , there was statistical significance （P 〈 0. 05 ） . Pulmonary artery systolic pressure of two groups decreased, and the observation group affects more obviously （ P 〈 0. 05 ） . Conclusion ： Kato Pury combined with sodium tanshinone lla sultbnate is good at treatment of chronic pulmonary heart disease, and Ihe drug price is low, and there is less adverse reactions, which is worthy of clinical application.